Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|September 1, 2011

BioPharm International

  • BioPharm International-09-02-2011
  • Volume 2011 Supplement
  • Issue 6

BioPharm International, September 2011 Supplement (PDF)

Biopharmaceutical Trends Report

Articles in this issue

about 15 years ago

Q&A with Francis S. Collins

about 15 years ago

Trends in Prefills

about 15 years ago

Navigating the Biosimilars Market

Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.